scispace - formally typeset
S

Sandro Barni

Researcher at Mario Negri Institute for Pharmacological Research

Publications -  516
Citations -  18062

Sandro Barni is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 61, co-authored 512 publications receiving 15500 citations. Previous affiliations of Sandro Barni include Hoffmann-La Roche & Marche Polytechnic University.

Papers
More filters
Journal ArticleDOI

Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis

Fausto Petrelli, +8 more
- 01 Feb 2017 - 
TL;DR: CC side should be acknowledged as a criterion for establishing prognosis in all stages of disease, and should represent a stratification factor for future adjuvant studies.
Journal ArticleDOI

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

Giancarlo Agnelli, +15 more
- 01 Oct 2009 - 
TL;DR: Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy, and future studies should focus on patients who are at a high risk for thrombolic events.
Journal ArticleDOI

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

Filippo Pietrantonio, +12 more
- 01 Mar 2015 - 
TL;DR: C- or P-based therapy did not increase the benefit of standard therapy or the BSC in RAS-wt/BRAF-mut CRC patients, and findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies.
Journal ArticleDOI

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martin, +622 more
- 01 Dec 2017 - 
TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.
Journal ArticleDOI

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

L. Crinò, +19 more
- 01 Nov 1999 - 
TL;DR: An increased response rate without changes in QoL and a similar overall survival, time to progression, and time to treatment failure for the GC when compared with the MIC regimen in the treatment of advanced NSCLC are reported.